For the Quarter Ending June 2025
North America
• The Rifaximin Price Index in the USA declined by 0.81% in April, followed by marginal gains of 0.20% in May and 0.07% in June, with spot prices moving from USD 263,100/MT in April to USD 263,807/MT in June.
• In April, product spot price weakened as downstream buyers reduced orders due to high inventories, and suppliers cut prices to clear stock.
• Elevated tariffs (145%) on Chinese imports prompted pre-shipment strategies that created excess stock, suppressing demand and weighing down the price index.
• The April product demand outlook was bearish, with buyers pausing new orders amid tariff uncertainty and high inventories.
• May saw a minor rebound as the 90-day tariff suspension encouraged cautious forward-buying, contributing to upward movement in the product spot price.
• Rising freight costs, peak season surcharges, and equipment shortages in May supported a modest increase in the product price forecast.
• In June, Rifaximin prices stayed relatively flat; market stability reflected balanced supply and moderate forward purchasing.
• Ongoing U.S.–China policy concerns in June led some buyers to mildly frontload, anticipating Q3 logistics disruptions.
• Domestic demand remained stable across all Q2 months, especially in the GI and infectious disease segments.
• For July 2025, the product price forecast leans toward an increase, driven by expected port congestion, delayed shipments, and cautious procurement behavior.
APAC
• The Rifaximin Price Index in China fell by 0.77% in April, followed by a marginal uptick of 0.19% in May and 0.05% in June. This reflects a near-stable quarter shaped by subdued demand and moderate supply conditions.
• In April, the product spot price dropped due to weak international demand, mounting backlogs, and export hurdles stemming from 145% U.S. tariffs, which sharply impacted Chinese pharmaceutical competitiveness.
• Ongoing inventory overhangs and order cancellations from the U.S. led suppliers to offer aggressive discounts, driving down prices despite adequate availability—highlighting a negative product demand outlook at the start of Q2.
• China’s manufacturing contraction in April (PMI at 49.0) worsened port congestion and disrupted logistics, further reducing seller flexibility and dampening Rifaximin’s price index.
• In May, product spot prices rebounded slightly to RMB 263,500/MT as freight disruptions persisted, but steady production post-Labour Day holidays and firm inventory coverage kept prices largely stable.
• Temporary suspension of U.S. tariffs led to modest export interest; some U.S. buyers resumed procurement to rebuild stocks, creating a neutral product demand outlook without prompting a sharp shift in prices.
• By June, the price index rose marginally amid forward ordering by international clients and manageable supply levels, while logistics-related freight increases nudged exporters to adjust prices modestly.
• June saw steady production cost trends with no major imbalances, as Chinese manufacturers aligned output to demand, maintaining calm market dynamics through the end of Q2.
• For July 2025, prices are likely to increase slightly, supported by steady domestic buying from formulation units, moderate overseas demand, and continued stability in manufacturing and logistics.
• The product price forecast suggests that manageable inventories and stable factory operations will maintain supply-side discipline, while forward ordering and regular restocking offer modest price support.
Europe
• The Rifaximin Price Index in Germany declined by 0.77% in April 2025, reaching USD 263,087/MT, pressured by oversupply caused by US tariff redirections and subdued domestic demand.
• Product spot price dropped sharply in April due to increased volumes redirected from the US to Germany and pre-stocking ahead of the May holidays, leaving buyers with surplus inventories.
• Product demand outlook remained weak in April as buyers held off purchases amid congestion at ports like Hamburg and Rotterdam, while pharma procurement activity stayed flat.
• In May 2025, the Price Index rose marginally by 0.19% to USD 263,590/MT, reflecting a balance between stable demand and rising shipping constraints across Northern Europe.
• Although port congestion and Rhine water-level issues extended lead times in May, pre-booked shipments kept inventory levels adequate and stabilized product spot price movements.
For the Quarter Ending March 2025
North America
Rifaximin prices in the U.S. remained relatively stable in Q1 2025, despite varying market pressures. In January, anticipated 10% tariffs on Chinese goods led importers to accelerate shipments, temporarily increasing demand. However, effective supply chain planning and manageable port delays from California wildfires kept prices steady.
In February, prices declined due to improved Chinese output post-holidays, soft domestic demand, and reduced shipping costs. Buyers showed restraint amid economic uncertainty, inflation concerns, and potential tariff risks on Chinese and Indian pharmaceuticals. Many had already restocked in January, dampening February’s purchasing activity.
By March, prices edged higher as buyers ramped up procurement ahead of new trade barriers. The imposition of further tariffs on China and other key partners by former President Trump on March 4 spurred anticipatory buying. Slightly easing inflation and improved sentiment also contributed to firmer demand.
Overall, Q1 was marked by cautious procurement, geopolitical tensions, and fluctuating demand, with price movement kept largely in check through effective supply chain adaptation and forward purchasing strategies.
Asia Pacific
In Q1 2025, Rifaximin prices in China experienced a modest upward trend driven by persistent supply constraints and steady demand from the pharmaceutical and healthcare sectors. January saw a slight price increase due to reduced manufacturing activity ahead of the Lunar New Year, combined with pre-holiday bulk orders and exporters rushing shipments before impending U.S. tariffs. In February, production delays extended due to the prolonged holidays, while steady foreign demand—particularly from European buyers amid trade tensions with the U.S.—intensified pressure on limited inventories. Prices continued to rise marginally in March as output gradually improved but remained insufficient to match the strong demand. Domestic consumption was supported by fiscal stimulus and restocking efforts ahead of scheduled plant maintenance, while foreign buyers accelerated procurement in anticipation of further trade restrictions. Throughout the quarter, market sentiment stayed firm, with suppliers maintaining upward pricing strategies amid tight availability. Overall, the quarter was marked by a delicate supply-demand imbalance, geopolitical trade uncertainty, and cautious restocking that sustained moderate price increases.
Europe
In Q1 2025, the Rifaximin market in Germany displayed notable price fluctuations influenced by shifting economic sentiment, supply chain dynamics, and downstream demand trends. January saw a moderate price increase as improved business morale, early inventory restocking, and pre-Lunar New Year demand from Asia bolstered procurement activity. The pharmaceutical and healthcare sectors, anticipating steady demand, contributed to firm buying interest. However, in February, prices declined due to ample supply from earlier stockpiling, weakened consumer sentiment amid political uncertainty, and favorable import conditions—including reduced freight costs and a stronger Euro—leading to subdued demand and increased competition among sellers. In March, prices rose again, supported by tightening supply conditions linked to port congestion and labor unrest in Europe. Renewed restocking efforts and more confident buying behavior—partly due to a marginal decline in Eurozone inflation—boosted demand from downstream sectors. Overall, Q1 was characterized by alternating phases of robust restocking and cautious procurement, shaped by a complex interplay of economic optimism, logistical challenges, and evolving pharmaceutical demand.
For the Quarter Ending December 2024
North America
In the fourth quarter of 2024, Rifaximin prices in the U.S. exhibited a mixed trend influenced by economic factors, consumer sentiment, and market conditions. October saw a decline in prices due to economic uncertainty, inflation concerns, and weakened demand. The upcoming presidential election and potential interest rate changes added to market caution, resulting in reduced consumer spending and slower corporate investments. Additionally, external disruptions like hurricanes and strikes further exacerbated market hesitation.
In contrast, November brought price stability, supported by steady demand from the pharmaceutical and healthcare sectors, favorable exchange rates, and improved supply chain efficiency following the resolution of strikes. Healthy inventory levels ensured a balanced market.
By December, Rifaximin prices remained stable, despite a slight dip in consumer confidence and reduced seasonal demand. Proactive inventory buildup and concerns over potential tariffs and strikes helped maintain sufficient supply. While inflation and tariff uncertainty kept the market cautious, suppliers adjusted pricing slightly to stay competitive, contributing to a steady market outlook.
Asia Pacific
In Q4 2024, Rifaximin prices in China experienced a gradual upward trend, primarily driven by a series of positive economic factors. In October, a boost in China’s manufacturing sector, fueled by government stimulus and easing monetary policies, led to higher domestic and export demand, pushing prices slightly higher. The depreciation of the yuan also made exports more competitive, contributing to the price increase. November saw a continuation of this trend, with factory activity expanding and export orders rising, driving further demand and increasing production costs due to higher raw material prices. This translated to a modest price rise as manufacturers passed on costs to consumers. By December, prices stabilized, supported by consistent demand from key sectors such as pharmaceuticals and healthcare, and a steady export volume. Manufacturers maintained regular production levels in anticipation of the Chinese Lunar New Year, while end-users built inventories. Overall, Q4 reflected moderate price increases, driven by domestic growth and external demand, culminating in a balanced market by December.
Europe
In Q4 2024, Rifaximin prices in Germany experienced a gradual decline, influenced by a range of economic factors. In October, cautious consumer spending, driven by ongoing inflation concerns, and a significant drop in shipping container prices created a softer market environment. Despite these pressures, supply levels remained stable, and businesses adjusted logistics strategies, which helped moderate the pace of price declines.
November brought a slight continuation of the downward trend as demand from key sectors remained weak. Inflation concerns began to ease, and energy prices fell, contributing to further downward pressure on prices. Additionally, lower retail performance and a slight dip in consumer spending in Germany added to the overall subdued market sentiment.
By December, the market continued its mild decline, with hesitant buying activity, a weaker euro, and sufficient inventory levels combining to exert downward pressure. Though purchasing slowed and logistical challenges persisted, concerns over inflation and potential price volatility contributed to a cautious market atmosphere. Suppliers focused on clearing inventory as the year came to a close, helping maintain a relatively stable, though slightly lower, price level. Overall, Q4 2024 was marked by a moderately declining market for Rifaximin, driven by cautious spending and a range of external economic pressures.
FAQs
1. Why were Rifaximin prices mostly stable across regions in Q2 2025?
Prices stayed largely flat due to balanced demand and supply. North America, APAC, and Europe saw only slight month-to-month changes in the Price Index, as high inventories, cautious restocking, and tariff-related uncertainty restrained sharp movements.
2. How did U.S.–China tariffs affect Rifaximin trade flows?
The 145% U.S. tariff in April led to frontloaded shipments and excess inventory in the U.S., while Chinese exporters faced weak orders and offered discounts. A 90-day tariff suspension in May spurred some cautious restocking globally but didn’t drastically shift demand.
3. What role did logistics and inflation play in regional pricing?
Shipping delays, container shortages, and inland transport issues (e.g., Rhine water levels in Europe) increased costs slightly. However, easing inflation in some areas helped keep production cost trends stable, preventing major price surges.
4. What is the Rifaximin price forecast for July 2025?
Prices are expected to rise slightly in all regions due to projected port congestion, delayed shipments, and cautious forward buying ahead of peak season logistics pressure.
